Clinical Edge Journal Scan

Current psoriatic lesions or a personal history of psoriasis correlates with PsA disease activity


 

Key clinical point: Patients with psoriatic arthritis (PsA) who had a personal history of psoriasis (pPsA) or a family history of psoriasis and current psoriatic lesions (fPsA/PSO) showed a higher disease activity (DA) and more severe axial joint destruction than those with merely a family history of psoriasis (fPsA).

Major finding: Patients with fPsA/PSO vs. fPsA had higher Disease Activity (DA) Index for PsA (DAPSA; 21.94 vs. 18.41; P = .046) and Bath Ankylosing Spondylitis DA Index (BASDAI; 4.09 vs. 3.74; P = .031) scores and more severe sacroiliitis (odds ratio [OR] 0.508; P = .037). The DAPSA ( P = .927) and BASDAI ( P = .716) scores were similar in patients with pPsA and fPsA/PSO.

Study details: Findings are from a prospective single-center, cross-sectional study including 296 patients with PsA, of which 145 had pPsA, 96 had fPsA, and 55 had fPsA/PSO.

Disclosures: This study was supported by the National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Li S-S et al. Exploring the association between history of psoriasis (PSO) and disease activity in patients with psoriatic arthritis (PsA). Rheumatol Ther. 2022 (May 17). Doi: 10.1007/s40744-022-00455-8

Recommended Reading

Commentary: Factors in Psoriatic Arthritis Development and Treatment Response, June 2022
Psoriatic Arthritis ICYMI
Serum brodalumab levels linked with treatment outcomes in patients with psoriasis
Psoriatic Arthritis ICYMI
Izokibep improves multiple psoriatic arthritis symptoms in phase 2 study
Psoriatic Arthritis ICYMI
Biologics, Women, and Pregnancy: What’s Known?
Psoriatic Arthritis ICYMI
Psoriatic Arthritis Treatment Basics
Psoriatic Arthritis ICYMI
Bimekizumab calms psoriatic arthritis in phase 3 ‘BE’ trials
Psoriatic Arthritis ICYMI
Enthesitis resolves regardless of medication used in PsA
Psoriatic Arthritis ICYMI
Upadacitinib offers effective disease control in PsA
Psoriatic Arthritis ICYMI
Real-world study confirms benefits of golimumab on work productivity and QoL in PsA
Psoriatic Arthritis ICYMI
Identifying clinical characteristics of difficult-to-treat PsA
Psoriatic Arthritis ICYMI